SPECIAL NOTICE
99 -- TECHNOLOGY/BUSINESS OPPORTUNITY ?High Density Protein Translation System?
- Notice Date
- 4/28/2023 9:31:42 AM
- Notice Type
- Special Notice
- NAICS
- 325411
— Medicinal and Botanical Manufacturing
- Contracting Office
- LLNS � DOE CONTRACTOR Livermore CA 94551 USA
- ZIP Code
- 94551
- Solicitation Number
- IL-13113
- Response Due
- 5/28/2023 10:00:00 AM
- Point of Contact
- Yash Vaishnav, Phone: 9254223538, Charlotte Eng, Phone: 9254221905
- E-Mail Address
-
vaishnav1@llnl.gov, eng23@llnl.gov
(vaishnav1@llnl.gov, eng23@llnl.gov)
- Description
- Opportunity: Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration to further develop and commercialize its novel system for high density protein translation. Background: Protein manufacturing is a large and growing industry, and provides researchers, clinicians, patients, and consumers the necessary solutions for research, therapy, pharmaceuticals, and nutritional needs. The current industry standard for mass protein fabrication consists of large facilities where genetically-modified cells are cultured to create the desired proteins. These production facilities are slow, expensive as well as labor-intensive as the large fermenting tanks filled with genetically engineered bacterial or mammalian cells, which require constant maintenance and care to ensure the product is properly made and treated. If overlooked, the cultures in the tanks could produce unwanted protein products, resulting in decreased production yield and quality.� Additionally, the types of proteins produced in this conventional method are limited due to their inherent instability and/or toxic properties to the cells that create them.� Cell-free protein manufacturing can overcome these shortcomings, but it has different disadvantages, e.g. the yield of protein is quite limited because of low density of ribosomes and diffusion and the system is not reusable compared to fermentation systems. If these limitations can be surmounted, a cell-free approach could revolutionize the production of proteins that maximizes yield and portability while minimizing latency and cost. Description: Combining the principles of nanotechnology, cell-free protein synthesis and microfluidics, LLNL researchers have developed a reusable, portable programmable system that can create purified, concentrated protein product in vitro in a microfluidic device containing nucleic acids. �Creating high-density arrays for in vitro protein synthesis within a microfluidic device can be achieved by attaching ribosomes to nanotubes that provide additional attachment sites along their length, resulting in a significant increase in ribosomal density on a surface by adding that third dimension.� � At the heart of this invention is the microfluidic reaction module, a chamber comprised of billions of nanotubes (2 billion/cm2) containing ribosomes that allows for high surface area (~1,000 times the surface area of flat surface), which maximizes protein translation rate.� To rapidly produce virtually any protein, a gene template and components required for in vitro transcription and translation can be injected into this reaction module. �After protein synthesis, the translation products and reactants are washed out of the reaction module.� The concentration and/or filter module(s) are then used to remove reaction byproducts and unused reactants from the reaction module to produce a purified target protein concentrate. Advantages/Benefits:� Protein configurations are not limited by their instability/toxicity within cells, which is a drawback with industrial manufacturing with largescale fermentation tanks Increased production yield and quality via novel ribosomal attachment and precise control over protein translation machinery compared to protein synthesis methods based on biological cells Faster and more cost-effective mass production of protein therapeutics Portable and on-demand; the technology enables production of a patient-specific protein in small quantity at point-of-care (hospitals) in response to demand. Compatible with all known linking chemistries and appropriate for various substrates Reusable for producing the same or other proteins since ribosomes are tethered to nanotube arrays Enables creation of proteins with novel functions since LLNL�s novel high density protein translation system is an open system Potential Applications:� Manufacturing of proteins for Therapeutics (including those suitable for personalized medicine approach) Biothreat response/recovery Research and development (e.g. study of ribosomes in the nanodomain) Development Status:� Current stage of technology development: TRL-2 LLNL has filed for patent protection on this invention. U.S. Patent Application Publication No. 2020/0255881 CELL-FREE PROTEIN SYNTHESIS SYSTEMS published 8/13/2020 LLNL is seeking industry partners with a demonstrated ability to bring such inventions to the market. Moving critical technology beyond the Laboratory to the commercial world helps our licensees gain a competitive edge in the marketplace. All licensing activities are conducted under policies relating to the strict nondisclosure of company proprietary information.� Please visit the IPO website at https://ipo.llnl.gov/resources for more information on working with LLNL and the industrial partnering and technology transfer process. Note:� THIS IS NOT A PROCUREMENT.� Companies interested in commercializing LLNL's High Density Protein Translation System should provide an electronic OR written statement of interest, which includes the following: 1.�������� Company Name and address. 2.�������� The name, address, and telephone number of a point of contact. 3.�������� A description of corporate expertise and/or facilities relevant to commercializing this technology. Please provide a complete electronic OR written statement to ensure consideration of your interest in LLNL's High Density Protein Translation System. The subject heading in an email response should include the Notice ID and/or the title of LLNL�s Technology/Business Opportunity and directed to the Primary and Secondary Point of Contacts listed below. Written responses should be directed to: Lawrence Livermore National Laboratory Innovation and Partnerships Office P.O. Box 808, L-779 Livermore, CA� 94551-0808 Attention:�� IL-13113
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/dbf7c52d074740808fd44a6f5d7eb4ff/view)
- Place of Performance
- Address: Livermore, CA, USA
- Country: USA
- Country: USA
- Record
- SN06665864-F 20230430/230428230109 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |